Bal Pharma Ltd (BALPHARMA)

₹100.50%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Bal Pharma Ltd share Performance

₹100.1
₹104
₹100.5
0.40%
Low
Day's Volatility:3.88%
High
3.48%
₹80
₹132.2
₹100.5
20.40%
Low
52 Weeks Volatility:51.94%
High
31.54%

Returns %
1 Month Return	-3.23 %
3 Month Return	-19.41 %
1 Year Return	22.79 %

Market Stats
Previous Close	₹100.50
Open	₹103.45
Volume	10.10K
Upper Circuit	-
Lower Circuit	-
Market Cap	₹158.83Cr

Company Information

BPL, a member of Macrolabs group, was incorporated in May 1987 and took over a pharmaceutical product manufacturing unit in Bangalore worth Rs 25.18 lac. The company manufactures and markets, pharmaceutical formulations such as paracetamol, aluminium hydroxide and povidone iodine. It came out with a public issue in Feb 1995 for the manufacturing of bulk drugs and expansion of pharmaceutical formulations. Additions to product range include AZIWIN CAFIMOL, CORTIDERM, Zanovid, Aziwin Dry Syrup, Meloxi Ocium, M Progit, MPS and Cardiac Specialities, AmilorideBenzydamine and Ebastine were added in 2002. BPL promotes its products through the sales force of the Macrolabs group and plans to launch its own soon. The unit has become a division of Bal Pharma Limited, thus marking an expansion in the drug production.

Share Price: ₹100.50 per share as on 06 May, 2024 12:34 PM
Market Capitalisation: ₹158.83Cr as of today
Revenue: ₹81.66Cr as on December 2023 (Q4 23)
Net Profit: ₹0.85Cr as on December 2023 (Q4 23)
Listing date: 08 May, 2006

Organisation	Bal Pharma Ltd
Headquarters	Bangalore
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Fundamentals of Bal Pharma Ltd

Insights on Bal Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 48.64% of holdings in Mar 2024 quarter
NO EFFECT
FII Holding Unchanged
Foreign Institutions holdings remained unchanged at 0.13% of holdings in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 57.1% return, outperforming this stock by 34.3%
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 122.4% return, outperforming this stock by 129.4%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.23% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 0.95 Cr → 0.89 Cr (in ₹), with an average decrease of 6.3% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 92.68 Cr → 81.76 Cr (in ₹), with an average decrease of 11.8% per quarter
NEGATIVE IMPACT
Price Dip
In the last 3 months, BALPHARMA stock has moved down by -19.4%